RIPK3 and neoplasm: Thirteen weeks after AOM-DSS regimen (day 91), lack of RIPK3 promoted marked tumor growth in the middle and distal part of the colon (Figure 1D and 1E), which closely mirrors the pattern seen in human CRC.